腹腔镜袖状胃切除术后六个月启动司美格鲁肽对长期减重与代谢结局的影响:单中心初步研究
该回顾性单中心研究纳入88例首次行腹腔镜袖状胃切除术(LSG)的患者,其中43例因减重不理想或平台期在术后6个月启动司美格鲁肽辅助治疗,45例仅常规随访。12个月和24个月时,司美格鲁肽组BMI更低、体重更轻、%TWL与%EWL更大,且HDL胆固醇更高、总胆固醇和甘油三酯更低,代谢谱更优。结论提示术后司美格鲁肽可为减重不足患者带来更优长期减重与心血管代谢获益。
要点
- LSG术后6个月启动司美格鲁肽可显著改善12及24个月减重指标
- 司美格鲁肽组24个月代谢谱更优:HDL更高、总胆固醇和甘油三酯更低
- 研究为单中心回顾性初步研究,需更高质量证据验证
核心结论
- LSG术后6个月启动司美格鲁肽辅助治疗与更优长期减重及心血管代谢结局相关。
- 术后司美格鲁肽可能为LSG后减重不足患者提供有效且安全的策略。
研究设计与样本
- 回顾性单中心研究,纳入88例首次行LSG的患者。
- 45例仅术后标准随访,43例因减重不理想或平台期在术后6个月启动司美格鲁肽辅助治疗。
- 在基线及术后6、12、24个月评估体重、BMI、%TWL、%EWL、HbA1c、血脂和血压。
主要发现
- 术后6个月(司美格鲁肽启动前)两组各项指标无显著差异。
- 12个月时司美格鲁肽组BMI更低、体重更轻、%TWL与%EWL更大。
- 24个月时减重获益持续,且HDL胆固醇更高、总胆固醇和甘油三酯更低。
临床怎么用
- 对LSG术后6个月出现减重不足或平台期的患者,可考虑启动司美格鲁肽辅助治疗。
- 启动后需在12和24个月持续评估体重、BMI、%TWL、%EWL及代谢指标。
局限性
- 单中心回顾性设计,样本量有限,属初步研究。
- 原文未报告随机化、盲法及混杂因素控制等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although laparoscopic sleeve gastrectomy (LSG) is an effective treatment for severe obesity, some patients experience suboptimal weight loss or an early weight-loss plateau during postoperative follow-up. Semaglutide has emerged as an effective pharmacological option for obesity management; however, evidence regarding its use after bariatric surgery remains limited. This study evaluated the impact of adjunctive semaglutide therapy initiated six months after LSG on long-term weight loss and metabolic outcomes. MATERIALS AND METHODS: This retrospective single-center study included 88 patients who underwent primary LSG. Patients were divided into two groups: 45 patients underwent standard postoperative follow-up after LSG, whereas 43 patients received adjunctive semaglutide therapy initiated six months after surgery because of suboptimal weight loss or weight-loss plateau. Anthropometric and metabolic parameters, including body weight, body mass index (BMI), percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), glycated hemoglobin (HbA1c), lipid profile, and blood pressure, were evaluated at baseline and at 6, 12, and 24 months after surgery. RESULTS: No significant differences were observed between the groups six months after surgery, immediately before semaglutide initiation. At 12 months, patients receiving semaglutide achieved significantly lower BMI, lower body weight, and greater %TWL and %EWL. These benefits persisted at 24 months, with significantly greater weight loss and a more favorable metabolic profile, including higher HDL cholesterol and lower total cholesterol and triglyceride concentrations. CONCLUSIONS: Adjunctive semaglutide therapy initiated six months after laparoscopic sleeve gastrectomy was associated with significantly greater long-term weight loss and improved cardiometabolic outcomes compared with surgery alone. These findings suggest that postoperative semaglutide may represent an effective and safe strategy for patients experiencing suboptimal weight loss following sleeve gastrectomy.
引用
- Jeske P, Roleder J, Zastawna K, et al. The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study. Surg Endosc. 2026. PMID: 42850299. doi:10.1007/s00464-026-13505-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。